Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· October 22, 2026
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
View original at finance.yahoo.comTelitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy Vor Biopharma Annualized eGFR slope of -0.6 vs…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
At 104 weeks TELIGAN demonstrated substantial proteinuria reduction and durable kidney protection; annualized eGFR slope approaching zero, lower rates of kidney function deterioration and sustained proteinuria reductions after transition to every-other-week dosing reinforce telitacicept's clinical potential and add to evidence supporting dual BAFF/APRIL inhibition.
60% confidenceTELIGAN met the Stage B primary endpoint, with a statistically significant difference in annualized eGFR slope through 104 weeks versus placebo.
60% confidenceTelitacicept reduced the risk of confirmed ≥30% and ≥40% eGFR declines by 89% and 81%, respectively.
60% confidence
Cité dans ces articles de Via News
- A Phase 3 kidney result holds up for two years while the AI-tech selloff tests biotech's funding →
- Biotech Grows Up: A Phase 3 Win, a Profitable Incyte and Royalty Income, While the Early Pipeline and AI Drugs Still Have to Prove Themselves →
- Biotech's Science Is Advancing While Its Funding Backdrop Tightens: What the Verified Numbers Show →